- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
More ▼
Key statistics
On Friday, Axsome Therapeutics Inc (0HKF:LSE) closed at 72.96, 31.13% above the 52 week low of 55.64 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 72.96 |
Average volume | 195.33 |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 3.49bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 20 minutes, as of May 31 2024 19:11 BST.
More ▼